Use of Novel Sinusonic Device for Prevention of Community Acquired Upper Respiratory Infection (URI)

Use of Novel Sinusonic Device for Prevention of Community Acquired Upper Respiratory (URI)

This study aims to test the safety, efficacy and potential mechanism of action of the SinuSonic device on adults with upper respiratory infection (URI). SinuSonic is a medical device that utilizes sound and pressure combined with normal breathing. The study will have 2 aims. Aim 1 willdetermine if Sinusonic decreases the number of URIs experienced during an 8 week fall URI season. Subjects will use an active device (positive expiratory pressure and 128 Hz) or a sham device (no positive expiratory pressure and 1,000 Hz) for 1 min tid for 8 weeks. Aim 2 will determine if Sinusonic decreases the severity and duration of community acquired viral URIs. Subjects will use active or sham device as above.

Inclusion Criteria:

• Adults 18 years or older with no transient symptoms of any URI or allergies at baseline.

Exclusion Criteria:

• Any transient ENT condition that may impact upper airway to include acute sinusitis or otitis.
• Any upper respiratory illness within last 2 weeks
• TSS will be measured at baseline as described above and must be <9 for inclusion (Eccles etal).
• Topical decongestant use in last week
• Current nasal crusting or history of ulceration or perforation
• History of severe nose bleeding within last 3 months
• Known pregnancy
• Immunosuppressed condition or on immune modulating medications such as prednisone or chemotherapy
• Allergic sensitivity to silicone or any other component of device
• Inability to read and understand English
• Inability to perform treatment due to underlying medical condition